肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

欧盟批准Imfinzi（durvalumab）一线治疗广泛期小细胞肺癌

2020-09-07 Allan MedSci原创

DurvalumabImfinzi广泛期小细胞肺癌PD-L1单抗Imfinzi
关注

阿斯利康（AstraZeneca）的Imfinzi（durvalumab）已获欧盟批准，Imfinzi（durvalumab）可与多种化疗药物一线治疗患有广泛期小细胞肺癌（ES-SCLC）的成人患者。

广泛期小细胞肺癌（extensive-stage small cell lung cancer，ES-SCLC）约占小细胞肺癌（（small cell lung cancer，SCLC）的2/3，治疗以化疗为主，辅助放疗等综合治疗。ES-SCLC是一种高度侵袭性、快速恶化的肺癌形式，尽管对化学疗法有最初反应，但通常会复发，这突出表明了对新型治疗方法的迫切需求。

近日，阿斯利康（AstraZeneca）的Imfinzi（durvalumab）已获欧盟批准，Imfinzi（durvalumab）可与多种化疗药物一线治疗患有广泛期小细胞肺癌（ES-SCLC）的成人患者。

在CASPIAN III期临床试验中，相比于单独化疗，Imfinzi联合化疗一线治疗显示出显著的总体生存期（OS）获益（13.0个月 vs. 10.3个月）以及客观缓解率的提高（68％ vs. 58％）。

阿斯利康（AstraZeneca）肿瘤学业务部执行副总裁Dave Fredrickson表示：“在广泛性小细胞肺癌患者中，这是第一种能同时改善生存期和应答率的免疫疗法”。

 

原始出处：

http://www.pharmatimes.com/news/az_imfinzi_bags_new_approval_for_lung_cancer_1347556

评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=898112, encodeId=b3d78981125d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388e5381768, createdName=ms7000001395190706, createdTime=Mon Nov 09 23:05:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912438, encodeId=ad25191243889, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 13 10:56:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886277, encodeId=95d18862e7f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Sep 18 08:07:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883878, encodeId=72af8838e8d1, content=赞👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c5416416, createdName=ms9000001304242802, createdTime=Wed Sep 09 14:08:42 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883482, encodeId=cf3488348232, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 08 07:23:21 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883431, encodeId=8b7c8834318a, content=<a href='/topic/show?id=b0408e15710' target=_blank style='color:#2F92EE;'>#英飞凡#</a>用于广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，进一步拓展，在国内，AZ的PD-L1势头生猛呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=295, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87157, encryptionId=b0408e15710, topicName=英飞凡), TopicDto(id=47089, encryptionId=5e2e4e08988, topicName=小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Sep 07 22:36:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883394, encodeId=24ea88339469, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09cb5416436, createdName=ms2000000156567565, createdTime=Mon Sep 07 20:26:00 CST 2020, time=2020-09-07, status=1, ipAttribution=)]
    2020-11-09 ms7000001395190706

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=898112, encodeId=b3d78981125d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388e5381768, createdName=ms7000001395190706, createdTime=Mon Nov 09 23:05:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912438, encodeId=ad25191243889, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 13 10:56:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886277, encodeId=95d18862e7f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Sep 18 08:07:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883878, encodeId=72af8838e8d1, content=赞👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c5416416, createdName=ms9000001304242802, createdTime=Wed Sep 09 14:08:42 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883482, encodeId=cf3488348232, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 08 07:23:21 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883431, encodeId=8b7c8834318a, content=<a href='/topic/show?id=b0408e15710' target=_blank style='color:#2F92EE;'>#英飞凡#</a>用于广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，进一步拓展，在国内，AZ的PD-L1势头生猛呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=295, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87157, encryptionId=b0408e15710, topicName=英飞凡), TopicDto(id=47089, encryptionId=5e2e4e08988, topicName=小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Sep 07 22:36:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883394, encodeId=24ea88339469, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09cb5416436, createdName=ms2000000156567565, createdTime=Mon Sep 07 20:26:00 CST 2020, time=2020-09-07, status=1, ipAttribution=)]
    2020-09-13 snf701207

    #mAb#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=898112, encodeId=b3d78981125d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388e5381768, createdName=ms7000001395190706, createdTime=Mon Nov 09 23:05:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912438, encodeId=ad25191243889, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 13 10:56:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886277, encodeId=95d18862e7f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Sep 18 08:07:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883878, encodeId=72af8838e8d1, content=赞👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c5416416, createdName=ms9000001304242802, createdTime=Wed Sep 09 14:08:42 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883482, encodeId=cf3488348232, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 08 07:23:21 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883431, encodeId=8b7c8834318a, content=<a href='/topic/show?id=b0408e15710' target=_blank style='color:#2F92EE;'>#英飞凡#</a>用于广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，进一步拓展，在国内，AZ的PD-L1势头生猛呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=295, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87157, encryptionId=b0408e15710, topicName=英飞凡), TopicDto(id=47089, encryptionId=5e2e4e08988, topicName=小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Sep 07 22:36:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883394, encodeId=24ea88339469, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09cb5416436, createdName=ms2000000156567565, createdTime=Mon Sep 07 20:26:00 CST 2020, time=2020-09-07, status=1, ipAttribution=)]
    2020-09-18 14818eb4m67暂无昵称

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=898112, encodeId=b3d78981125d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388e5381768, createdName=ms7000001395190706, createdTime=Mon Nov 09 23:05:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912438, encodeId=ad25191243889, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 13 10:56:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886277, encodeId=95d18862e7f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Sep 18 08:07:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883878, encodeId=72af8838e8d1, content=赞👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c5416416, createdName=ms9000001304242802, createdTime=Wed Sep 09 14:08:42 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883482, encodeId=cf3488348232, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 08 07:23:21 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883431, encodeId=8b7c8834318a, content=<a href='/topic/show?id=b0408e15710' target=_blank style='color:#2F92EE;'>#英飞凡#</a>用于广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，进一步拓展，在国内，AZ的PD-L1势头生猛呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=295, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87157, encryptionId=b0408e15710, topicName=英飞凡), TopicDto(id=47089, encryptionId=5e2e4e08988, topicName=小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Sep 07 22:36:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883394, encodeId=24ea88339469, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09cb5416436, createdName=ms2000000156567565, createdTime=Mon Sep 07 20:26:00 CST 2020, time=2020-09-07, status=1, ipAttribution=)]
    2020-09-09 ms9000001304242802

    赞👍

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=898112, encodeId=b3d78981125d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388e5381768, createdName=ms7000001395190706, createdTime=Mon Nov 09 23:05:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912438, encodeId=ad25191243889, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 13 10:56:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886277, encodeId=95d18862e7f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Sep 18 08:07:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883878, encodeId=72af8838e8d1, content=赞👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c5416416, createdName=ms9000001304242802, createdTime=Wed Sep 09 14:08:42 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883482, encodeId=cf3488348232, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 08 07:23:21 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883431, encodeId=8b7c8834318a, content=<a href='/topic/show?id=b0408e15710' target=_blank style='color:#2F92EE;'>#英飞凡#</a>用于广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，进一步拓展，在国内，AZ的PD-L1势头生猛呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=295, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87157, encryptionId=b0408e15710, topicName=英飞凡), TopicDto(id=47089, encryptionId=5e2e4e08988, topicName=小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Sep 07 22:36:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883394, encodeId=24ea88339469, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09cb5416436, createdName=ms2000000156567565, createdTime=Mon Sep 07 20:26:00 CST 2020, time=2020-09-07, status=1, ipAttribution=)]
    2020-09-09 zhaojie88

    #广泛期小细胞肺癌#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=898112, encodeId=b3d78981125d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388e5381768, createdName=ms7000001395190706, createdTime=Mon Nov 09 23:05:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912438, encodeId=ad25191243889, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 13 10:56:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886277, encodeId=95d18862e7f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Sep 18 08:07:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883878, encodeId=72af8838e8d1, content=赞👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c5416416, createdName=ms9000001304242802, createdTime=Wed Sep 09 14:08:42 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883482, encodeId=cf3488348232, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 08 07:23:21 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883431, encodeId=8b7c8834318a, content=<a href='/topic/show?id=b0408e15710' target=_blank style='color:#2F92EE;'>#英飞凡#</a>用于广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，进一步拓展，在国内，AZ的PD-L1势头生猛呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=295, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87157, encryptionId=b0408e15710, topicName=英飞凡), TopicDto(id=47089, encryptionId=5e2e4e08988, topicName=小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Sep 07 22:36:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883394, encodeId=24ea88339469, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09cb5416436, createdName=ms2000000156567565, createdTime=Mon Sep 07 20:26:00 CST 2020, time=2020-09-07, status=1, ipAttribution=)]
    2020-09-09 swallow

    #Imfinzi#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=898112, encodeId=b3d78981125d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388e5381768, createdName=ms7000001395190706, createdTime=Mon Nov 09 23:05:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912438, encodeId=ad25191243889, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 13 10:56:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886277, encodeId=95d18862e7f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Sep 18 08:07:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883878, encodeId=72af8838e8d1, content=赞👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c5416416, createdName=ms9000001304242802, createdTime=Wed Sep 09 14:08:42 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883482, encodeId=cf3488348232, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 08 07:23:21 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883431, encodeId=8b7c8834318a, content=<a href='/topic/show?id=b0408e15710' target=_blank style='color:#2F92EE;'>#英飞凡#</a>用于广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，进一步拓展，在国内，AZ的PD-L1势头生猛呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=295, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87157, encryptionId=b0408e15710, topicName=英飞凡), TopicDto(id=47089, encryptionId=5e2e4e08988, topicName=小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Sep 07 22:36:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883394, encodeId=24ea88339469, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09cb5416436, createdName=ms2000000156567565, createdTime=Mon Sep 07 20:26:00 CST 2020, time=2020-09-07, status=1, ipAttribution=)]
    2020-09-09 chenwq14

    #欧盟批准#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=898112, encodeId=b3d78981125d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388e5381768, createdName=ms7000001395190706, createdTime=Mon Nov 09 23:05:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912438, encodeId=ad25191243889, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 13 10:56:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886277, encodeId=95d18862e7f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Sep 18 08:07:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883878, encodeId=72af8838e8d1, content=赞👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c5416416, createdName=ms9000001304242802, createdTime=Wed Sep 09 14:08:42 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883482, encodeId=cf3488348232, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 08 07:23:21 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883431, encodeId=8b7c8834318a, content=<a href='/topic/show?id=b0408e15710' target=_blank style='color:#2F92EE;'>#英飞凡#</a>用于广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，进一步拓展，在国内，AZ的PD-L1势头生猛呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=295, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87157, encryptionId=b0408e15710, topicName=英飞凡), TopicDto(id=47089, encryptionId=5e2e4e08988, topicName=小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Sep 07 22:36:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883394, encodeId=24ea88339469, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09cb5416436, createdName=ms2000000156567565, createdTime=Mon Sep 07 20:26:00 CST 2020, time=2020-09-07, status=1, ipAttribution=)]
    2020-09-08 14818eb4m67暂无昵称

    学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=898112, encodeId=b3d78981125d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388e5381768, createdName=ms7000001395190706, createdTime=Mon Nov 09 23:05:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912438, encodeId=ad25191243889, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 13 10:56:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886277, encodeId=95d18862e7f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Sep 18 08:07:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883878, encodeId=72af8838e8d1, content=赞👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c5416416, createdName=ms9000001304242802, createdTime=Wed Sep 09 14:08:42 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883482, encodeId=cf3488348232, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 08 07:23:21 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883431, encodeId=8b7c8834318a, content=<a href='/topic/show?id=b0408e15710' target=_blank style='color:#2F92EE;'>#英飞凡#</a>用于广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，进一步拓展，在国内，AZ的PD-L1势头生猛呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=295, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87157, encryptionId=b0408e15710, topicName=英飞凡), TopicDto(id=47089, encryptionId=5e2e4e08988, topicName=小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Sep 07 22:36:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883394, encodeId=24ea88339469, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09cb5416436, createdName=ms2000000156567565, createdTime=Mon Sep 07 20:26:00 CST 2020, time=2020-09-07, status=1, ipAttribution=)]
    2020-09-07 lovetcm

    #英飞凡#用于广泛期#小细胞肺癌#，进一步拓展，在国内，AZ的PD-L1势头生猛呀

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=898112, encodeId=b3d78981125d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=388e5381768, createdName=ms7000001395190706, createdTime=Mon Nov 09 23:05:53 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912438, encodeId=ad25191243889, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sun Sep 13 10:56:09 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=886277, encodeId=95d18862e7f1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=178, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Fri Sep 18 08:07:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883878, encodeId=72af8838e8d1, content=赞👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=190, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a10c5416416, createdName=ms9000001304242802, createdTime=Wed Sep 09 14:08:42 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350172, encodeId=7aa613501e2f9, content=<a href='/topic/show?id=3e7f491e23e' target=_blank style='color:#2F92EE;'>#广泛期小细胞肺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49172, encryptionId=3e7f491e23e, topicName=广泛期小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416498, encodeId=d7f91416498c3, content=<a href='/topic/show?id=93ce9e60cc' target=_blank style='color:#2F92EE;'>#Imfinzi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9760, encryptionId=93ce9e60cc, topicName=Imfinzi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34be3191285, createdName=swallow, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590034, encodeId=c9ff1590034ac, content=<a href='/topic/show?id=2d1c63118e9' target=_blank style='color:#2F92EE;'>#欧盟批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63118, encryptionId=2d1c63118e9, topicName=欧盟批准)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0d617780998, createdName=chenwq14, createdTime=Wed Sep 09 10:56:09 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883482, encodeId=cf3488348232, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=204, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 08 07:23:21 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883431, encodeId=8b7c8834318a, content=<a href='/topic/show?id=b0408e15710' target=_blank style='color:#2F92EE;'>#英飞凡#</a>用于广泛期<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>，进一步拓展，在国内，AZ的PD-L1势头生猛呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=295, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87157, encryptionId=b0408e15710, topicName=英飞凡), TopicDto(id=47089, encryptionId=5e2e4e08988, topicName=小细胞肺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Mon Sep 07 22:36:18 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883394, encodeId=24ea88339469, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09cb5416436, createdName=ms2000000156567565, createdTime=Mon Sep 07 20:26:00 CST 2020, time=2020-09-07, status=1, ipAttribution=)]
    2020-09-07 ms2000000156567565

    赞

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析

PACIFIC是第一项证明能够改善无法切除的III期非小细胞肺癌（NSCLC）生存的研究，将改写III期NSCLC的治疗标准。III期无法切除NSCLC的5年生存率为15%~30%左右，在长达几十年中

Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌

本研究旨在评估奥拉帕利联合PD-L1抑制剂durvalumab用于携带胚系BRCA1突变或BRCA2突变的转移性乳腺癌患者的疗效和安全性。

Lancet：Durvalumab-铂-依托泊苷一线治疗小细胞肺癌

研究认为，Durvalumab-铂-依托泊苷作为一线治疗手段可显著延长广泛性小细胞肺癌患者生存期

durvalumab与tremelimumab的组合未能在NSCLC研究中击败化疗

阿斯利康近日宣布，与标准铂类化疗相比，Imfinzi（durvalumab）联合使用tremelimumab治疗初治IV期非小细胞肺癌（NSCLC）患者的III期NEPTUNE研究未能达到总生存期（OS）的主要终点。

durvalumab联合tremelimumab治疗膀胱癌：无法改善OS

阿斯利康近日宣布，一项针对PD-L1抑制剂Imfinzi（durvalumab）的III期研究（单药治疗以及与抗CTLA4抗体tremelimumab联合使用）未能达到主要终点。

AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高

高危HER2阴性乳癌的新辅助治疗疗效一直有待临床提升，此前PDL1单抗durva+奥拉帕尼在BRCA突变HER2阴性乳癌中，疾病控制率80%。这项研究名为MEDIOLA的II期临床试验，探索了PD-L

拓展阅读

黄岩教授、张力教授团队研究揭示：度伐利尤单抗联合奥拉帕利在ES-SCLC维持治疗中显示生存获益

该研究为PARP抑制剂联合免疫治疗在广泛期小细胞肺癌一线维持治疗中的应用提供了首批前瞻性临床证据，也提示DNA甲基化状态可能作为指导患者筛选的潜在生物标志物。

朱慧教授：从诊疗争议到登顶JCO，广泛期小细胞肺癌患者一线治疗后仅脑转移，要不要换二线方案？

为了向中国临床医生精准传递这一重磅研究的学术价值，梅斯医学特邀主要研究者（PI）朱慧教授，围绕研究设计背后的核心理念及临床意义进行深入解读，现将采访内容整理成文，以飨读者。

读书报告 | IMforte研究：芦比替定联合阿替利珠单抗维持治疗广泛期小细胞肺癌

本表明广泛期小细胞肺癌一线阿替利珠单抗维持治疗中加入芦比替定，显著改善了无进展生存期和总生存期，且具有临床意义。

邬麟教授：中国真实世界数据破解ES-SCLC治疗困境，PS≥2脆弱人群OS显著延长至12.33个月 | 2025 CSCO

特邀请湖南省肿瘤医院 邬麟教授分享肺癌领域的一些重大进展。

JITC | GOIRC-01-2019 CeLEBrATE研究：卡铂、依托泊苷、阿替利珠单抗联合贝伐珠单抗一线治疗广泛期小细胞肺癌的疗效与安全性

该研究旨在评估卡铂、依托泊苷、阿替利珠单抗和贝伐珠单抗联合一线治疗ES-SCLC的疗效，结果显示，贝伐珠单抗可能增强卡铂-依托泊苷-阿替利珠单抗一线治疗ES-SCLC的疗效，并保持总体可管理的安全性。

STTT：钟南山院士团队创新疗法：诱导化疗联合“双艾”组合为广泛期小细胞肺癌患者带来显著生存获益

研究首次提出在未经治疗的ES-SCLC患者中，通过诱导化疗缩小肿瘤后再联合卡瑞利珠单抗和阿帕替尼，兼顾了疗效和安全性，为ES-SCLC的治疗提供了新的思路和希望。